Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer

1 Jan 2024

Abstract excerpt

Abstract Background Olaparib targets the DNA repair pathways and has revolutionized the management of metastatic castration resistant prostate cancer (mCRPC). Treatment with the drug should be guided by genetic testing; however, published economic evaluations did not consider olaparib and genetic testing as codependent technologies. This study aims to assess the cost-effectiveness of BRCA germline testing to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38439629
DOI: 10.1017/s0266462324000011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancerPMID 38439629Read ↗

The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers.Semantic proximity Read ↗

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.Semantic proximity Read ↗

Olaparib for Chinese Metastatic Castration-resistant Prostate Cancer: A Real-World Study of Efficacy and Gene Predictive AnalysisSemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness AnalysisSemantic proximity Read ↗

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.Semantic proximity Read ↗

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.Semantic proximity Read ↗

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.Semantic proximity Read ↗

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.